Evidence map›Paper›PMID 38496603›Full record

ArticlebioRxiv : the preprint server for biology2023

Targeting LINC00152 activates cAMP/Ca

Ozge Saatci, Rashed Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Metin Cetin, Unal Metin Tokat, Mustafa Emre Gedik and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 6 countries.

Ozge SaatciDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0002-0124-044X
Rashed AlamDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Kim-Tuyen Huynh-DamDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC, 29208, USA.
Aynur IsikDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, TURKEY.
Meral UnerDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, TURKEY.
Nevin BelderDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, TURKEY.
Pelin Gulizar ErsanDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, TURKEY.
Metin CetinDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0001-9963-8407
Unal Metin TokatDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, TURKEY.
Mustafa Emre GedikDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0003-0522-0267
Hilal BalDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, TURKEY.
Ozlem Sener SahinDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Yasser RiazalhosseiniDepartment of Human Genetics, McGill University, Montreal, Quebec, CANADA.
Denis ThieffryDépartement de biologie de l'Ecole normale supérieure, PSL Université, 75005 Paris, FRANCE.
Daniel GautheretInstitute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, CNRS, CEA, 91190, Gifsur-Yvette, FRANCE.
Besim OgretmenDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Sercan AksoyDepartment of Medical Oncology, Hacettepe University Cancer Institute, 06100, Ankara, TURKEY.
Aysegul UnerDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, TURKEY.
Aytekin AkyolDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, TURKEY.
Ozgur SahinDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0002-8033-7089
Medical University of South Carolina · USBilkent University · TRHacettepe University · TRCentre National de la Recherche Scientifique · FRCancer Institute (WIA) · INUniversité Paris Sciences et Lettres · FRUniversity of South Carolina · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
RESEARCH PILOT PROJECTS PROGRAMP30GM103339 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OGRETMEN, BESIM · 2012 to 2016
$5.4M
MUSC FACIL EXPANSION &RENOV: SLE C06RR015455 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CROUCH, ROSALIE K · 2002 to 2002
$2.0M
Overcoming chemoresistance in triple negative breast cancerR01CA267101 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Ozgur Sahin · 2022 to 2026
$1.8M
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplificationR01CA251374 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI SAHIN, OZGUR · 2021 to 2025
$1.7M
NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA251374NCI NIH HHS R01 CA267101NCRR NIH HHS C06 RR015455NIGMS NIH HHS P30 GM103339
6 · The paper itself

Abstract

Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER+) breast cancer, constituting around 75% of all cases. However, emergence of resistance is common, necessitating the identification of novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen resistance via blocking tamoxifen-induced ferroptosis, an iron-mediated cell death. Mechanistically, inhibiting LINC00152 reduces the mRNA stability of phosphodiesterase 4D (

Indexed as

calciumcAMPER+ breast cancerferroptosislncRNAtamoxifen resistance

Identifiers

PMID38496603
PMCPMC10942410
OpenAlexW4388399135

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.